Roche Diagnostics Launches Operations in Nigeria, Reinforces Commitment to Expanding Access to Quality Healthcare
*Lagos, Nigeria – June 2025* — Roche Diagnostics has officially launched its new legal diagnostics entity in Nigeria, marking a major step in the company’s strategic push to expand access to high-quality in-vitro diagnostics (IVD) across the African continent.
The move aligns with Roche’s 10-Year Diagnostics Strategy for Africa, which aims to increase access to diagnostics tenfold. With over 70 years of experience on the continent, Roche is leveraging its expertise in infrastructure development, systems optimization, workforce training, and capacity building to improve healthcare outcomes in Nigeria and other parts of Africa.
Africa carries 25% of the global disease burden but receives just 1% of the global health budget and comprises only 3% of the world’s health workforce. Roche says its investment in Nigeria is designed to help reverse this imbalance by fostering partnerships with local governments and funding institutions to strengthen the healthcare ecosystem.
The new legal entity will allow Roche Diagnostics to work more directly with healthcare providers and customers, improving supply chain efficiency and deepening collaboration with public and private sector stakeholders. The goal, according to the company, is to support Nigeria’s journey toward achieving Universal Health Coverage (UHC).
ALSO READ: Quantum Computing is Coming: Are Your Printers Protected?
“We are creating a more responsive diagnostics ecosystem by working closely with local stakeholders,” said Roberto Taboada, Country Manager, Roche Diagnostics, Africa. “This is a significant step towards achieving sustainable healthcare transformation in Nigeria.”
The Nigerian office will also serve as a regional hub for Roche’s operations in Anglophone West Africa, enabling quicker access to diagnostic solutions across multiple countries.
“We strengthen our role in delivering innovative diagnostics solutions that improve healthcare outcomes for more patients where it is needed most,” added Jonathan Keytel, Director of Strategy and Innovation, Roche Diagnostics, Africa. “Nigeria is a critical market, and this investment supports our long-term vision for healthcare in Africa.”
Roche, founded in 1896, is a global leader in in-vitro diagnostics and the world’s largest biotechnology company. The firm continues to pioneer advances in personalized healthcare, striving to discover and develop medical solutions that save and improve lives worldwide.
.